Utilizing advanced RNA-sequencing techniques and rigorous bioinformatics analysis, this study identified gene signatures predicting responsiveness to pembrolizumab monotherapy. T-cell-inflamed gene expression profile was predictive for better treatment response, while angiogenesis, monocytic myeloid-derived suppressor cell, and stroma/epithelial-mesenchymal transition/TGFβ gene signatures were associated with lower treatment response. See related article by Cristescu et al., p. 1680.
©2022 American Association for Cancer Research.